4immune Therapeutics has developed the first CAR T therapy to target and destroy the autoreactive T cells responsible for specific autoimmune disorders. Our multi-component CAR system with its novel adaptor molecule (CAL) bridges autologous or allogeneic CAR T cells to the offending autoreactive T cells to kill the cells and stop the disease in its tracks.
Our first therapeutic targets early-stage type 1 diabetes, presently an incurable disease. There are many excellent therapies that successfully tamper down symptoms or prolong onset of the disease and have enhanced the quality of life for many patients. Others are achieving therapeutic value with beta cells transplants for late-stage patients. Our mission is to eradicate the disease-causing cells early in the process before too much pancreatic tissue damage has ensued and conquer autoimmune disorders for life.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.4immunetx.com/
4immune Therapeutics Questions
4Immune Therapeutics's website is https://www.4immunetx.com/
4Immune Therapeutics's LinkedIn profile is https://www.linkedin.com/company/4immune-therapeutics
4Immune Therapeutics's industry is
Biotechnology Research
4Immune Therapeutics's top competitors are
Orna Therapeutics,
Qubind (Acquired),
Warrantyhub,
Ab Biosciences,
100xbio,
Abata Therapeutics,
Ipsius,
Stemcellerant,
Cullinan Therapeutics,
Adicet Bio, Inc.
4Immune Therapeutics's categories are Biotechnology Research
4Immune Therapeutics's founding year is 2021
